Endometrial cancer (EM) is the most common malignant tumor in women, most often of reproductive age. EC are detected, according to various sources, in 25 - 50% of women under the age of 50 years. We analyzed the results of examination and treatment of 98 patients. The criterion for inclusion in this study was a morphologically verified squamous EC of stages IB2, IIB and IIIB, the results showed that it is advisable to subject endometrial cancer patients with identified metastases to a special one (chemo, chemoradiotherapy followed by radical operations), as this leads to improved results (in in our study by more than 20%) and an increase in the life expectancy of these patients, also, depending on the stage, depth of tumor invasion and those treated with neoadjuvant chemotherapy and subsequent radical operations: for example, the five-year relapse-free and overall survival rates were 79.6% and 87 .5%, respectively, in patients with EC stages IB2 - IIIB, which is approximately 20% higher than similar indicators among patients who underwent only combined radiation therapy.

Malignant neoplasms, endometrial cancer, neoadjuvant chemotherapy

Alcazar, J.L. Three-Dimensional Power Doppler Ultrasound for Predicting Response and Local Recurrence After Concomitant Chemoradiation Therapy for Locally Advanced Carcinoma of the Cervix / J.L. Alcazar, S. Arribas, R. MartinezMonge et al. // Int. J. Gynecol. Cancer. ‒ 2016. ‒ Vol. 26, N 3. ‒ P. 534-538.

Amin, M.B. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging / M.B. Amin, F.L. Greene, S.B. Edge et al. // CA Cancer J. Clin. ‒ 2017. ‒ Vol. 67, N 2. ‒ P. 93-99.

Guyot, M. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies / M. Guyot, C. Hilmi, D. Ambrosetti // Oncotarget. ‒ 2017. ‒ Vol. 8, N 6. ‒ P. 9174-9188.

Colombo, N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / N. Colombo, S. Carinelli, A. Colombo et al. // Ann. Oncol. ‒ 2012. ‒ Vol. 23 Suppl. 7. ‒ P. vii27-32.

D'Agostino, G. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin / G. D'Agostino, M. Distefano, S. Greggi et al. // Cancer Chemother. Pharmacol. ‒ 2002. ‒ Vol. 49, N 3. ‒ P. 256-260.

Hu, K. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy / K. Hu, W. Wang, X. Liu et al. // Radiat. Oncol. ‒ 2018. ‒ Vol. 13, N 1. ‒ P. 249.

Huguet, F. Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion / F. Huguet, O.M. Cojocariu, P. Levy et al. // Int. J. Radiat. Oncol. Biol. Phys. ‒ 2008. ‒ Vol. 72, N 5. ‒ P. 1508-1515.

Jennings, T.S. Results of selective use of operative laparoscopy in gynecologic oncology / T.S. Jennings, P. Dottino, J. Rahaman et al. // Gynecol. Oncol. ‒ 1998. ‒ Vol. 70, N 3. ‒ P. 323-328.

Koh, W.J. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology / W.J. Koh, N.R. Abu-Rustum, S. Bean et al. // J. Natl. Compr. Canc. Netw. ‒ 2019. ‒ Vol. 17, N 1. ‒ P. 64-84.

Kubik, S. Assessment of the relationship between serum squamous cell carcinoma antigen (SCC-Ag) concentration in patients with locally advanced squamous cell carcinoma of the uterine cervix and the risk of relapse / S. Kubik, M. MoszynskaZielinska, J. Fijuth et al. // Prz. Menopauzalny. ‒ 2019. ‒ Vol. 18, № 1. ‒ P. 23-26.

Marlow, L.A.V. Understanding the heterogeneity of cervical cancer screening non-participants: Data from a national sample of British women / L.A.V. Marlow, A.J. Chorley, J. Haddrell et al. // Eur. J. Cancer. ‒ 2017. ‒ Vol. 80. ‒ P. 30-38.

Moloney, F. Comparison of MRI and high-resolution transvaginal sonography for the local staging of cervical cancer / F. Moloney, D. Ryan, M. Twomey et al. // J. Clin. Ultrasound. ‒ 2016. ‒ Vol. 44, N 2. ‒ P. 78-84.

Marita, A. Long-term survival following neoadjuvant chemotherapy and concomitant radiochemotherapy in locally advanced cervical cancer: results of the Oncology Institute "Prof. Dr. Ion Chiricuta" experience / A. Marita, C. Ordeanu, A. Rancea et al. // J. Med. Life. ‒ 2018. ‒ Vol. 11, N 1. ‒ P. 42-50.

Scappaticci, F.A. Mechanisms and future directions for angiogenesis-based cancer therapies / F.A. Scappaticci // J. Clin. Oncol. ‒ 2002. ‒ Vol. 20, N 18. ‒ P. 3906- 3927.

197. Shoji, T. Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix / T. Shoji, E. Takatori, T. Saito et al. // Cancer Chemother. Pharmacol. ‒ 2013. ‒ Vol. 71, N 3. ‒ P. 657-662.